Last reviewed · How we verify
NCT07353138
Preoperative Neutrophil-to-Lymphocyte Ratio and Early Postoperative Pain After Septorhinoplasty
trial testing Observational Study in Neutrophil-to-Lymphocyte Ratio in 110 participants. Not yet recruiting.
15 March 2026
Quick facts
| Lead sponsor | Istinye University |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 110 |
| Start date | 1 January 2026 |
| Primary completion | 15 March 2026 |
| Estimated completion | 31 March 2026 |
Drugs / interventions tested
- Observational Study — full drug profile →
Conditions studied
- Neutrophil-to-Lymphocyte Ratio — all drugs for Neutrophil-to-Lymphocyte Ratio →
- Septorhinoplasty — all drugs for Septorhinoplasty →
Sponsor
Istinye University
Who can join
Adults 18 to 65, any sex, with Neutrophil-to-Lymphocyte Ratio or Septorhinoplasty. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This prospective, observational study investigates the relationship between early oxygen exposure and oxidative stress in adult intensive care unit patients with sepsis or septic shock. Fraction of inspired oxygen (FiO₂) administered during the first 24 hours of ICU admission will be recorded and analyzed in relation to changes in the uric acid/albumin ratio (UAR), a biomarker reflecting oxidative burden and inflammation. Serum uric acid and albumin levels will be measured at baseline and at 24 hours, and the percentage change in UAR will be calculated. Secondary analyses will examine associations between UAR changes, oxygenation indices, and 28-day mortality. The study aims to determine whether higher FiO₂ exposure is associated with increased oxidative stress and to evaluate the potential role of UAR as a clinically accessible marker of oxygen-related oxidative injury in septic ICU patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07353138
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Observational Study
Trials testing the same drug.
- NCT07534046 — Impact of Metabolic Disorders on cACLD Outcomes · not yet recruiting
- NCT07151768 — Prospective Validation of the Novel PVD-B65 Risk Score in Patients With Chronic Lung Disease and Pulmonary Hypertension · recruiting
- NCT06601439 — Utilization of Maternal Healthcare Services and Infant Feeding Practices · active not recruiting
- NCT06702436 — Invasive vs. Conservative Management in Cancer Patients With Non-ST Elevation MI (CAN-NSTEMI)" · completed
- NCT06089668 — An Observational Study to Evaluate Clinical Characteristics of Adult Patients With Suspected or Confirmed Melioidosis · completed
Other recruiting trials for Neutrophil-to-Lymphocyte Ratio
Currently open trials in the same condition.
- NCT06747481 — Neutrophil-to-lymphocyte Ratio and CA 19.9 as Predictors of Perineural Invasion in Pancreatic Cancer · recruiting
Other Istinye University trials
Trials by the same sponsor.
- NCT06963294 — Ketamine and Dexmedetomidine for Delirium in Joint Arthroplasty · NA · not yet recruiting
- NCT07528807 — Exercise, Pain Beliefs, and Activity Patterns in Musculoskeletal Pain · not yet recruiting
- NCT07520981 — Functional Capacity, Subjective Dyspnea and Fatigue in Smokers · not yet recruiting
- NCT07518095 — Serum Bicarbonate and Enteral Feeding Intolerance in Adult ICU: A Prospective Clinical Trial · not yet recruiting
- NCT07483190 — Effectiveness of Thoracoabdominal Nerve Block (M-TAPA) on Postoperative Pain Relief in Laparoscopic Hysterectomy · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07353138 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Istinye University
- Last refreshed: 20 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07353138.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing